Scientific Sessions 2026 Daily News: Friday, Nov. 6

Friday Nov. 6, 2026 Daily News #ScientificSessions26 AI, imagenomics and robotics could redefine how physicians assess cardiovascular risk and treat disease. Imagine a future where patient care relies less on invasive procedures while artificial intelligence, advanced imaging and precision medicine improve outcomes. It’s not far away, according to Patrick Serruys, MD, PhD, eFESC, FACC, who headlines this year’s Paul Dudley White International Lecture and Session. Serruys, a professor of interventional medicine and innovation at the University of Galway in Ireland, will draw on his research to present a bold forecast for coronary revascularization. His presentation, “Paul Dudley White Lecture: Coronary Revascularization in 2040,” is part of the Global Impact Program at Scientific Sessions. At the center of this technological transformation is a rapidly emerging discipline known as imagenomics (“image-nomics”), he said, which combines medical imaging with genomic, proteomic, lipidomic and metabolomic data to identify cardiovascular risk earlier and tailor treatment strategies to each patient. “Having forecasted in 2000 the impact of innovations like drug-eluting stents, coronary computed tomography angiography and bioresorbable scaffolds, our research examined the evolving landscape of coronary artery disease treatment, emphasizing artificial intelligence and omics sciences,” Serruys said. “Imagenomics — the integration of imaging and omics — will be a transformative tool, with AI enabling more personalized decisions between pharmacological and mechanical revascularization.” Serruys said cardiovascular care will expand beyond the measure of arterial blockages. It will shift to focus on biological risk. AI-powered analysis of genetic and imaging data will be a valuable tool for identifying patients at risk of developing coronary artery disease years before symptoms appear, he said. “With novel biomimetic peptides like CD31 covalently bound to metallic or polymeric implanted devices, current antiplatelet and anticoagulant therapies will become See PAUL DUDLEY WHITE, page 7 Welcome to Chicago! Patrick Serruys, MD, PhD, eFESC, FACC Paul Dudley White lecturer outlines profound tech impact on coronary care UPCOMING SESSION Paul Dudley White International Lecture and Session 1:15–2:30 p.m. | Friday, Nov. 6 N229 Bringing expert cardiovascular care within reach worldwide Where patients live should not determine the quality of cardiovascular care they receive. Yet geographic distance, limited resources and unequal access to specialized expertise continue to create disparities in patient outcomes. Emerging technologies, including artificial intelligence and innovative clinical networks, offer new opportunities to close those gaps by bringing expert-level decisionmaking closer to patients, regardless of their location. Translating those opportunities into practical, scalable solutions will be the focus Friday of the session “Reimagining Cardiovascular Care for Scalable Global Impact.” During the session, Derek P. Chew, MBBS, will explore strategies for expanding access to cardiovascular expertise in his presentation, “Bridging Innovation and Access: Implementing Scalable Cardiovascular Solutions Globally.” Among the most promising approaches to mitigating disparity is leveraging established clinical networks to support time-critical decisions for patients in rural and remote communities, where specialized care may be difficult to access, said Chew, a professor and director of cardiovascular medicine at the Victorian Heart Hospital, director of health informatics research at the Monash Victorian Heart Institute and See WORLDWIDE, page 6 Derek P. Chew, MBBS UPCOMING SESSION Reimagining Cardiovascular Care for Scalable Global Impact 11:30 a.m.–12:45 p.m. | Friday, Nov. 6 N229 First things first • Build your schedule. Browse the online program to explore sessions and create a personalized agenda. • Grab a guide. Pick up an Experience Sessions Guide at the convention center for information about meeting activities and experiences. • Use the meeting app. Download the mobile app to access interactive maps, livestreamed sessions, networking events and other meeting resources. The Science & Technology Hall opens tomorrow!

2 SCIENTIFIC SESSIONS DAILY NEWS | Friday, Nov. 6, 2026 Today at Sessions All sessions are located at the McCormick Place Convention Center unless otherwise noted. NEW FOR 2026 | Innovation Forum 8 a.m.–6 p.m. The American Heart Innovation Forum is a one-day, highenergy experience designed to help clinicians, scientists and innovators turn ideas into impact. Through candid conversations with founders, investors and industry leaders, participants will explore the real-world path from discovery to startup across cardiovascular and brain health. InnFm.01 | The Entrepreneur’s Journey: From Idea to Impact 8:05–8:55 a.m. | S100A InnFm.02 | Identifying HighValue Opportunities 9:05–9:55 a.m. | S100A InnFm.03 | Funding, Partnerships and Scaling Innovation 10:10–11 a.m. | S100A InnFm.04 | Fireside Conversation: AI and the Future of Cardiovascular Innovation 11:15 a.m.–12:05 p.m. | S100A InnFm.06 | American Heart Association as Your Innovation Partner 1:20–2:10 p.m. | S100A InnFm.07 | Venture Showcase: Companies Transforming Cardiovascular Health 2:25–3:15 p.m. | S100A InnFm.08 | Innovation Forum Early-Stage Pitch Competition 3:30–4:45 p.m. | S100A InnFm.09 | Closing Reflections: What Will Define the Next Decade of Cardiovascular Innovation? 5–5:45 p.m. | S100A Networking Reception 5:45–6:30 p.m. | S100 Foyer Use #ScientificSessions26 to share your highlights and join the conversation online. Guideline Programming CP.CVS.01 | AHA Young Hearts Clinical Guidelines and Statements in Action: Translating New Evidence Into Practice 8–9:15 a.m. | S103D CO.CVS.08 | The 5th Universal Definition of Myocardial Infarction: What’s New, and Why It Matters? 9:45–11 a.m. | S105ABC SA.ME.01 | Rethinking Coronary Revascularization: Less Invasive and More Strategic 4:45–6 p.m. | S105D BH.CVS.05 | The AHA/ASA 2026 Acute Ischemic Stroke Guidelines: Highlights Relevant for Cardiovascular Groups 4:45–6 p.m. | N230B Special Sessions BH.CVS.09 | Saving Hearts Is Not Enough: Why Brain Health Must Define the Future of Cardiovascular Care 1:15–2:30 p.m. | Special Session, North Hall, Level 3 VB.ME.05 | The Thrombo-Inflammatory Axis: Bridging the Vessel Wall, Blood and Bedside* 3–4:15 p.m. | Special Session, North Hall, Level 3 #ScientificSessions26 Welcome to Scientific Sessions 2026 in Chicago, where you will find the best in cardiovascular science and medicine. Early Career EC.01 | Early Career Networking Meet & Greet 11:30 a.m.–Noon | N228 EC.02 | Building Your Early Career With AHA — Early Career Day Opening Session Noon–1 p.m. | N228 EC.03 | From Fellow to Mid-Career: Mentorship, Sponsorship and Leadership Growth 1–1:50 p.m. | N228 EC.07 | Effective and Responsible Application of AI in Your Early Career 4–4:50 p.m. | N228 EC.08 | Developing Your Career for a Multidisciplinary Future: Lessons Learned From Cardio-Oncology 5–5:50 p.m. | N228 EC.15 | Navigating Early Career as an International Graduate 5–5:50 p.m. | N140 EC.11 | Early Career Investigator Showcase: Spotlight on AHA Funded Research — Basic Science 5–5:50 p.m. | N137 EC.09 | Dear Future Me: Dialogue on Mentorship and Career Evolution in Pediatric Cardiology for FITs and Early Career Faculty 5–5:50 p.m. | N226 EC.10 | Career Success Tips for the Early Career Interventionalist 5–5:50 p.m. | N136 Please see the Experience Scientific Sessions Program and the mobile app for all programming. *Not a CE accredited session. Global Impact GL-IMP.01 | Reimagining Cardiovascular Care for Scalable Global Impact 11:30 a.m.–12:45 p.m. | N229 GL-IMP.02 | Paul Dudley White International Lecture and Session 1:15–2:30 p.m. | N229 GL-IMP.03 | From Algorithms to Access: AI-Driven Innovation in Global Cardiovascular Care 3–4:15 p.m. | N229 GL-IMP.04 | Innovations in Women’s Cardiovascular Care: Improving Outcomes Worldwide 4:45–6 p.m. | N229 Don’t miss your chance to connect. View networking opportunities and events at #ScientificSessions26

3 #ScientificSessions26 ScientificSessions.org © NewAmsterdam Pharma B.V. 2026 09/26 UM-US--0028 NewAmsterdam Pharma is committed to developing novel, nonstatin, oral therapies that will potentially reduce patients’ ASCVD risk. ACC, American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease. Reference: 1. Palaniappan LP, Allen NB, Almarzooq ZI, et al. 2026 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2026;153:e275-e906. doi:10.1161/CIR.0000000000001412 2. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153:e00-e00. doi:10.1161/CIR.0000000000001423 NewAmsterdam Pharma is dedicated to Defusing ASCVD risk IT’S TIME TO EXPECT MORE Each day >2500 US adults die of CVD,1 despite available lipid therapies Visit us at BOOTH #3102 The 2026 ACC/AHA guideline broadens the focus beyond LDL-C.2 Scan to see why looking beyond LDL-C matters. Paid Advertisement Hypertrophic Cardiomyopathy Medical Society (HCMS) HCMS.01 | The Latest in Therapy for HCM 8–9:30 a.m. | S406A HCMS.02 | HCMS Abstract Oral Presentations 9:45–10:45 a.m. | S406A HCMS.03 | The Eugene Braunwald, MD, Lecture Session 10:45–11:15 a.m. | S406A The 2026 Eugene Braunwald, MD, Lectureship has been awarded to Scott Solomon, the Edward D. Frohlich Distinguished Chair, professor of medicine at Harvard Medical School and Brigham and Women’s Hospital. Following his passing in April 2026, this session serves as an active remembrance of Braunwald’s monumental contributions to hypertrophic cardiomyopathy. Explore Braunwald’s legacy at HeartQuarters, located in the Science & Technology Hall (Heart Hub, Booth 1). HCMS.04 | Cool New Gadgets and Interventions 1–2:15 p.m. | S406A HCMS.05 | Late Breaking Oral Abstracts 2:15–3:15 p.m. | S406A HCMS.06 | Living Well With HCM, Now and Into the Future 3:30–4:45 p.m. | S406A HCMS.07 | HCM405: CMI Troubleshooting in the Real World 4:45–5:30 p.m. | S406A HCMS.08 | HCMS Abstract Poster Board Presentations* 5:30–6:30 p.m. | S406B QCOR at Sessions QCOR.01 | Agentic AI in Cardiovascular Care: From Automation to Intelligent Workflows 8–9:15 a.m. | S106B QCOR.02 | The Great QCOR Debate: What Will Actually Improve Cardiovascular Outcomes? 9:30–10:45 a.m. | S106B QCOR.03 | QCOR Early Career Investigator Abstract Award Competition 10:45 a.m.–Noon | S106B QCOR.04 | QCOR Career Development and Networking Luncheon 12:15–1:30 p.m. | S105D QCOR.05 | QCOR Keynote Fireside Chat 1:30–2:15 p.m. | S106B QCOR.06 | Translating Prevention Guidelines Into Communities of Need 2:15–3:30 p.m. | S106B QCOR.06 | Translating Prevention Guidelines Into Communities of Need 2:15–3:30 p.m. | S106B QCOR.07 | The Cost of Progress: How Policy Shapes Access, Affordability and Innovation in Cardiovascular Care 3:45–5 p.m. | S106B View the Industry Programming Guide Cardiovascular- Kidney-Metabolic Certificate Program CKM.01 | CKM Symposium Session 1: Characterizing Risk 1–1:50 p.m. | S105ABC CKM.02 | CKM Symposium Session 2: Best Practices for CKM Risk Management 1:50–2:40 p.m. | S105ABC CKM.03 | CKM Symposium Session 3: Multimorbidity: Hypertension, Hyperlipidemia and Cardiovascular Disease 3:10–4 p.m. | S105ABC CKM.04 | CKM Symposium Session 4: Access, Implementation and Care 4–4:50 p.m. | S105ABC

4 SCIENTIFIC SESSIONS DAILY NEWS | Friday, Nov. 6, 2026 A virtual replica of a patient’s heart could help physicians predict treatment outcomes before an invasive procedure even begins. Researchers are bringing this technology, known as a cardiac digital twin, from the laboratory to clinical practice, opening new possibilities for personalized treatment of ventricular tachycardia (VT). The science, described this year in the New England Journal of Medicine, is part of the Friday session “Bioengineering the Gap From Basic Biology to Cardiovascular Therapy.” Natalia Trayanova, PhD, will discuss “Heart Digital Twins and AI: Engineering Personalized Roadmaps for Therapy.” Her research team develops patient-specific heart digital twins to guide the treatment of heart rhythm disorders. “These virtual reconstructions are built from data that comes from only that patient,” said Trayanova, who holds the Murray B. Sachs professorship in biomedical engineering and is a professor of medicine at Johns Hopkins University in Baltimore. Digital twin technology combines decades of physiological research with advanced computational modeling, she said, to create the highly detailed representations of each heart. Digital twins have predictive value, Trayanova said. “That point is important; otherwise, it’s just a computational model. With predictive value, it can guide decisions for precision medicine, which finds the right treatment for the right patient at the right time.” In the trial, heart digital twins were used to guide VT ablation. “We were the first ever to use digital twins in a clinical trial,” Trayanova said, noting that the research was conducted under a Food and Drug Administration investigational device exemption and showed that digital twin-guided ablation is safe and feasible. With their development based on information from individual hearts, digital twins stand in contrast to traditional artificial intelligence systems that identify patterns across large datasets. This distinction is critical, Trayanova said. The digital twin technology incorporates knowledge across multiple levels of biological organization, from cellular behavior and cell-tocell interactions to whole-organ function. By combining patientspecific imaging and clinical data with computational physiology, researchers can simulate disease processes and treatment responses before interventions occur, she said. Much of the team’s current work focuses on cardiac arrhythmias. These conditions can be dangerous and often are difficult to treat because every patient’s disease presents differently, she said. Digital twin models give physicians a noninvasive tool to better understand an individual’s condition and determine the most effective treatment strategy. In addition to the digital twin innovation, Trayanova’s team is pursuing multimodal AI approaches designed to predict patient risk for a range of cardiovascular conditions, including sudden cardiac death. Although AI and digital twins are fundamentally different technologies, Trayanova said AI can be used to accelerate digital twin simulations and enhance analytical capabilities. Pioneer showcases future of precision cardiology Digital twin technology can help find ‘the right treatment for the right patient at the right time.’ Learn the latest on HFmrEF/HFpEF in the American Heart Association’s podcast series and eModule. • Diagnosis • Heart Failure Phenotypes • Connection to Cardio-Kidney-Metabolic Syndrome • Medical and Device Therapies • Practical Application and Access to Treatment Funding for this American Heart Association educational program is provided by Bayer. Learn Now HFmrEF/HFpEF: From Symptoms to Solutions © Copyright 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. WF-1932190 9/26 PAID ADVERTISEMENT American Heart Association® Lifelong LearningTM UPCOMING SESSION Bioengineering the Gap From Basic Biology to Cardiovascular Therapy: BCVS Symposium Session 4 3–4:15 p.m. | Friday, Nov. 6 S102A Natalia Trayanova, PhD

5 #ScientificSessions26 ScientificSessions.org Hot topics in cardiovascular gene therapy Panel discussion to focus on genetic medicines. Targeting the genetic roots of cardiovascular disease is moving from scientific promise to clinical reality. But as gene-based therapies advance, questions about safety, delivery, effectiveness and cost are becoming increasingly important. Currently, the U.S. Food and Drug Administration has approved some therapies for a subset of conditions, while others are in clinical trials. Elizabeth McNally, MD, PhD, will outline the promises and challenges of gene therapy Friday during the panel discussion “Optimization of Therapies, Clinical Implementation Strategies and Communication Between Stakeholders,” as part of the Genomic and Precision Medicine Symposium: Cardiovascular Gene Therapy — Session 3. “We can expect discussions of different approaches to delivering genetic medicines and gene therapy ranging from siRNAs (small interfering RNAs) to adenoassociated viruses (AAVs) to gene editing,” said McNally, who is Elizabeth J. Ward Professor of Medicine and director of the Center for Genetic Medicine at Northwestern University’s Feinberg School of Medicine in Chicago. “This will include aspects of how we can best deliver these treatments to the heart while minimizing the (side)effects.” SiRNA can regulate gene expression, allowing selective reduction in the production of a specific protein through RNA interference. McNally said treatments such as patisiran and vutrisiran use RNA interference to target the TTR gene to treat transthyretin amyloid cardiomyopathy (ATTR-CM) and neuropathy. Antisense oligonucleotides (ASOs), such as inotersen and eplontersen, can also target TTR. “Clinically, there is a good experience with siRNA and ASO treatments, which are generally well tolerated,” McNally said. Another potential discussion topic is AAVs, which can be used as delivery mechanisms for gene replacement therapy, making them well suited to treat certain genetic disorders where a gene product is lacking. Researchers have developed newer AAVs with better ability to reach the heart. However, McNally said this line of therapy is not without its drawbacks. McNally said adeno-associated viral delivery can activate complement — part of the innate immune system that enhances the ability of antibodies to clear microbes and injured cells from an organism — and elicit toxicity in the liver and other organs. “This, along with immune responses to the virus and the gene product, can limit efficacy and also create side effects,” she said. McNally said gene editing is another promising potential therapy because it can correct underlying genetic defects, including those linked to genetic cardiovascular disease. Clinical trials are investigating the possibility of treating familial hypercholesterolemia and transthyretin amyloidosis. Although early results from those trials are promising, McNally said there is a need to proceed cautiously. “Gene editing requires careful attention to delivery mechanisms, both for efficacy and to minimize off-target effects,” she said. Whatever approach is taken, McNally said cardiologists should be aware of several important considerations. “Each approach needs to address overall molecular and clinical efficacy and address whether one dose is sufficient and what the barriers may be to repeat dosing,” she said. “Many of these therapeutic agents or drugs are very costly to produce and deliver, and so this needs to be carefully weighed. CARDIOVASCULAR – KIDNEY – METABOLIC HEALTH PASSPORT CHALLENGE Collect Insights. Shape the Future. Leave Inspired to Act. *SATURDAY, NOV. 7 AND SUNDAY, NOV. 8 | 9am – 4:30pm CST MONDAY, NOV. 9 | 9am – 3pm CST Heart.org/CKMHProfessional The American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative is made possible by Founding Sponsors Novo Nordisk and Boehringer Ingelheim, Supporting Sponsors Novartis Pharmaceuticals Corporation and Bayer, and Champion Sponsor DaVita. PAID ADVERTISEMENT © 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. 9/26 WF1772201 Show your commitment to understanding and implementing the 2026 Cardiovascular-Kidney- Metabolic (CKM) Syndrome Guideline by participating in the conference-wide CKM Health Passport Challenge. Find the QR Code at featured CKM Health destinations and tackle questions designed to strengthen your approach to CKM care. Every passport stop earns you another chance to win Beats Studio headphones, an Ember Mug, or complimentary registration to Scientific Sessions 2027. STOP BY BOOTH #2640 FOR YOUR CKM HEALTH PASSPORT MAP* CKM HEALTH WF-1772201 CKM Scientific Sessions Print Ads-_2026-7.indd 2 9/23/26 7:13 PM Elizabeth McNally, MD, PhD UPCOMING SESSION Genomic and Precision Medicine Symposium: Cardiovascular Gene Therapy — Session 3 4:45–5:45 p.m. | Friday, Nov. 6 S401D

6 SCIENTIFIC SESSIONS DAILY NEWS | Friday, Nov. 6, 2026 When it comes to treating structural heart disease, knowing when to intervene can be just as important as knowing how. With new technologies expanding treatment options, physicians face increasingly complex decisions about which patients will benefit most, which approaches to pursue and how long they can safely wait. These decisions will be explored at the Friday session “Lifetime Valve Care in 2026: Who to Treat, When to Intervene and Which Technology Wins?” Panelists will review current guidelines, emerging technologies and strategies for optimizing care across a patient’s life. Abdulla Damluji, MD, PhD, MBA, and Angela Lowenstern, MD, MHS, will co-moderate the session, which will include a presentation by Samir Kapadia, MD: “Tricuspid Intervention: Who Should We Treat, and When Is It Too Late?” Kapadia will focus on patient selection and personalized care plans for people with tricuspid regurgitation (TR). Although mild cases of TR often don’t present symptoms, more severe cases are associated with shortness of breath, extreme fatigue, peripheral swelling and abdominal bloating. Kapadia, who is chair of the department of cardiovascular medicine and holds the Jennifer and Robert McNeil Endowed Chair in Interventional Cardiology at Cleveland Clinic in Ohio, said these patients must be considered for TR intervention — and quickly. “The timing of tricuspid regurgitation treatment is very important and not widely studied or understood,” Kapadia said. “Even when diuretics are able to control edema, one should consider TR treatment upon evidence of episodic decompensation, RV (right valve) dysfunction, increasing dose of diuretics, etc.” Untreated patients with TR are at high risk of poor quality of life, morbidity and mortality. Traditionally, Kapadia said, clinicians have treated TR with diuretics, which only ease symptoms. However, in the past three years, the Food and Drug Administration has approved two minimally invasive tricuspid-valve surgeries. • Transcatheter edge-to-edge repair for tricuspid regurgitation (T-TEER) uses a catheter to attach a clip that helps close the valve. In one 2023 clinical trial, T-TEER improved patient quality-of-life scores and reduced the level of TR severity. Almost every patient in the study (98.3%) who underwent T-TEER was free from major adverse events at 30 days. • Transcatheter tricuspid valve replacement (TTVR) uses a catheter to implant a device inside the impaired tricuspid valve. According to a 2025 review paper, TTVR may improve patient quality of life, reduce TR, increase RV function and even reverse RV remodeling. Although both procedures carry risks, such as internal bleeding, device detachment or incompatibility, their approval and integration into clinical practice have changed the game for patients with TR, Kapadia said. One of the biggest factors in choosing a surgical approach is a patient’s anatomy. Kapadia also stressed the importance of early referral for tricuspid valvesurgery. “It is too late once severe right valve dysfunction has produced ascites,” he said. This elevated pressure in the RV can cause extreme discomfort, interfere with diuretics and lead to backward venous congestion or RV heart failure. Timing is everything in tricuspid regurgitation care New minimally invasive therapies expand treatment options, but identifying the right patients before irreversible damage occurs remains critical. UPCOMING SESSION Lifetime Valve Care in 2026: Who to Treat, When to Intervene and Which Technology Wins? 3–4:15 p.m. | Friday, Nov. 6 S106A Samir Kapadia, MD chief scientific and medical officer of the Heart Foundation of Australia. Integrating machine learning into routine clinical workflows could further improve decision-making in these settings. “Embedding these into electronic workflows will enable us to scale expert decision-making 24/7, regardless of geography,” he said. Australia has a long history of developing clinical networks to support cardiovascular care across vast geographic distances. Chew said these networks provide a foundation for newer approaches that incorporate algorithms into routine clinical workflows, helping clinicians make informed decisions in settings where expert consultation may not be readily available. Other initiatives are extending specialized decision-making into community settings, particularly general practice. Chew said these efforts are beginning to narrow gender-based differences in care. But technology alone cannot eliminate disparities. The challenges of geographic distance often are compounded by socioeconomic disadvantage, Chew said, creating additional obstacles to implementing innovative care models. Inadequate infrastructure, limited resources and insufficient funding can hinder the adoption of digital solutions, especially in underresourced communities. Persistent biases also threaten equitable care, especially for women, Indigenous populations and patients whose first language is not English, he said. Regulatory and funding barriers must also be addressed. Overcoming all these challenges requires health systems to rethink how they allocate resources, especially specialized clinical expertise. “Maintaining a focus on equity and affordability means that we need to be better at directing the scarce resource of expertise to where it is needed, rather than by supply alone,” Chew said. Chew identified several opportunities to accelerate progress, including national data systems that can consistently integrate evidencebased insights into clinical practice. “The data systems and analytic requirements of this are large, but the capabilities continue to expand, and I’m confident that we can achieve this through the stewardship of data systems and healthcare funding in Australia,” he said. WORLDWIDE continued from page 1 Connect. Learn. Be Inspired. Early Career Networking & Mentor Reception Friday, Nov. 6 | 6-7:30 p.m. North Building, Level 1 Lobby Outside of Rooms N139-140 Connect with fellow early career healthcare professionals, meet experienced mentors and gain insights to help navigate your career path. Build meaningful relationships and discover new opportunities in healthcare. Supported by

7 #ScientificSessions26 ScientificSessions.org obsolete,” Serruys said. “Advances in photon-counting computed tomography and Fiber Optic RealShape promise high-resolution imaging with lower radiation, enhancing procedural safety and diagnostic accuracy. It is anticipated that robotics and 3D holograms in percutaneous and surgical revascularization will improve precision and resulting outcomes.” Large-scale research initiatives, including the UK Biobank Pharma Proteomics Project, the All of Us Research Program and the China Kadoorie Biobank, are creating the datasets needed for predictive and personalized cardiovascular medicine. Based on ongoing research, Serruys said he believes that future treatment decisions may increasingly favor pharmacological revascularization, where advanced drugs reverse plaque buildup and restore coronary function without surgical intervention. Serruys said his research also addresses the predictive feature that coronary CT angiography will deliver as a comprehensive “onestop shop” diagnostic platform by 2040. Physicians may use a single noninvasive scan to assess anatomy, blood flow, plaque characteristics and treatment options before deciding whether a patient needs medication, stenting or bypass surgery, he said. One of the most significant forecasts, Serruys said, involves a shift away from traditional coronary stents. Instead, younger patients with soft, noncalcified plaque may increasingly be treated with powerful anti-atherosclerotic medications that would regress plaque, reducing the need for mechanical interventions. Also, Serruys said next-generation bioresorbable scaffolds, drug-coated balloons and innovative bioadaptors are expected to advance medicine’s goal of “leaving nothing behind” after treatment. Unlike permanent metal stents, he said, these devices would gradually dissolve or restore natural vessel function over time. “The aging population will drive demand for mechanical interventions, with advancements in atherectomy and lithotripsy techniques improving outcomes in complex, calcified lesions,” Serruys said. “Our analysis outlines a future where myocardial revascularization becomes increasingly personalized, with technology-driven interventions redefining cardiovascular medicine.” Finally, Serruys said robotic-assisted procedures are likely to play a larger role by 2040. His research highlights the potential benefits of robotic percutaneous coronary intervention, including improved procedural precision, lower physician radiation exposure and future possibilities for remote intervention. Similar advances are occurring in robotic cardiac surgery, where minimally invasive procedures continue to gain momentum. But he cautioned that high costs, technical limitations and training requirements will remain barriers to widespread adoption. “In the future, cardiology clinics will likely resemble a technologyenabled precision medicine center, where disease is predicted, prevented and treated before major cardiac events occur,” Serruys said. “Dr. Paul Dudley White is widely regarded as a pioneer of preventive cardiology. He was a staunch advocate that lifestyle plays a critical role in the development and prevention of coronary artery disease,” Serruys added. “As a retired interventional cardiologist, I wholeheartedly embrace his vision. I believe the future of cardiovascular medicine lies in imagenomics and early prevention, combining a healthy lifestyle with potent, biomimetic antiatherogenic agents when lifestyle interventions alone are insufficient.” PAUL DUDLEY WHITE continued from page 1 Printed copies are available near the Science & Technology Hall entrance. View your customized Hypertension and Prevention Journey for #ScientificSessions26 Sponsored by Medtronic and Mineralys Therapeutics, Inc. Delta Dental is proud to collaborate with the American Heart Association’s Healthy Smiles, Healthy Hearts Initiative. Delta Dental is a registered trademark of Delta Dental Plans Association. Expand Your Understanding of the Dynamic Connection Between Oral and Cardiovascular Health Access our vodcast series, eModule, and other resources bringing the latest science and evidence-based strategies for you to learn about topics like patient safety, accurate blood pressure measurement, and how oral health can be associated with increased risk for cardiovascular disease and stroke risk. Multiple CE credits available, including ADA CERP. American Heart Association. Unauthorized use prohibited. WF-1928217 10/26 LEARN NOW PAID ADVERTISEMENT

3CPR Rachel Beekman, MD, FAHA T. J. Bishop, BS, NRP, NCEE, FAHA Ryan A. Coute, DO, FAHA Maya Dewan, MD, MPH, FAHA Kei Hayashida, MD, PhD, FAHA Chih-Hsin Hsu, MD, PhD, FAHA Ryan Huebinger, MD, FAHA Sarasa Isobe, MD, PhD, FAHA Benny L. Joyner, Jr., MD, MPH, FAHA Jing Li, MD, FAHA Timmy Li, PhD, FAHA Masashi Okubo, MD, MS, FAHA Catherine Ross, MD, FAHA Janek Senaratne, MD, MSc, FAHA Peng Zhang, MD, MS, FAHA ATVB Rihab Bouchareb, PhD, MSc, FAHA Paul Cheng, MD, PhD, FAHA Frederik Denorme, PhD, FAHA Ebru Erbay, MD, PhD, FAHA Sivareddy Kotla, PhD, FAHA Liping Liu, MD, PhD, FAHA Kunal Mahajan, MD, DM, FAHA Vidya Perera, PhD, FAHA Jordan S. Pober, MD, PhD, FAHA Amin Polzin, MD, FAHA Robert L. Raffai, PhD, FAHA Mohanakrishnan Sathyamoorthy, MD, FAHA Bhupesh Singla, PhD, FAHA Daniel Soffer, MD, FAHA Amber Stratman, PhD, FAHA Michal Toborek, MD, PhD, FAHA Kasey Vickers, PhD, FAHA Bruce Warden, PharmD, FAHA BCVS Shahid Baba, PhD, FAHA Shyam S. Bansal, PhD, FAHA Thomas Brett, PhD, FAHA Alex P. Carll, PhD, MSPH, FAHA Karthickeyan Chella Krishnan, PhD, FAHA Ann Chiao, PhD, FAHA Carlos L. del Rio, PhD, FAHA Yichen Ding, PhD, FAHA Carly Filgueira, PhD, FAHA Daniel Gallego-Perez, PhD, FAHA Ying Ge, PhD, FAHA Narasimman Gurusamy, PhD, MPharm, FAHA Tariq Hamid, PhD, FAHA Jason Hellmann, PhD, FAHA Camila Hochman-Mendez, PhD, FAHA Yun Huang, PhD, FAHA Vinod Kumar, DM, FAHA Simon Lebek, MD, FAHA Chi Fung Lee, PhD, FAHA Stephan E. Lehnart, MD, PhD, FAHA Rebecca D. Levit, MD, FAHA Cevher Ozcan, MD, FAHA Nicole H. Purcell, PhD, FAHA Vishwa Rajagopalan, PhD, FAHA Manuel Rosa-Garrido, PhD, FAHA Sarah M. Schumacher, PhD, FAHA Gaurav Sharma, PhD, MBA, FAHA Venkatesh Sundararajan, MPharm, PhD, FAHA Dhanendra Tomar, PhD, FAHA Suresh Kumar Verma, PhD, FAHA Junco Warren, PhD, FAHA Marcin Wysoczynski, PhD, FAHA Yang Kevin Xiang, PhD, FAHA CLCD Carl J. Ade, PhD, FAHA Tania Ahuja, PharmD, FAHA Jose A. Alvarez-Cardona, MD, FAHA Vidhu Anand, MBBS, FAHA Sajal Krishna Banerjee, MBBS, MD, FAHA Tyler Bloomer, MD, MS, FAHA Vanessa Blumer, MD, FAHA Frank Brozovich, MD, PhD, FAHA Neel Butala, MD, FAHA Larisa Cavallari, PharmD, FAHA Robert J. DiDomenico, PharmD, FAHA Elizabeth H. Dineen, DO, FAHA Jherie Ducombs, MD, FAHA Shunsuke Eguchi, MD, PhD, FAHA Stephanie Feldman, MD, FAHA Lusia Fomuso, PharmD, DBA, MPH, FAHA Michele Golino, MD, PhD, FAHA Waqas Haider, MD, MPH, FAHA Ijeoma Isiadinso, MD MPH, FAHA Christine Jellis, MBBS, PhD, MBA, FAHA Jimmy Kerrigan, MD, FAHA Efstratios Koutroumpakis, MD, FAHA Chayakrit Krittanawong, MD, FAHA Gina LaRocca, MD, MHSc, FAHA Hak Seung Lee, MD, FAHA David T. Linker, MD, FAHA Angela Lowenstern, MD, MHS, FAHA Trejeeve Martyn, MD, MSc, FAHA Giselle C. Melendez, MD, FAHA Sumeet Singh Mitter, MD, MSc, FAHA Freny Vaghaiwalla Mody, MD, FAHA Selma Mohammed, MD, PhD, FAHA Rajkumar Nadakinamani, MBBS, MD, FAHA Michael G. Nanna, MD, MHS, FAHA Kazunori Omote, MD, PhD, FAHA Nosheen Reza, MD, FAHA Henri Roukoz, MD, MSc, FAHA Jenna Skowronski, MD, FAHA Kevin B. Sneed, PharmD, FAHA Pallavi Solanki, MD, MBA, FAHA Kamala P. Tamirisa, MD, FAHA Marysia S. Tweet, MD, MS, FAHA Sunil K. Vasireddi, MD, FAHA Margus Viigimaa, MD, PhD, FAHA Kris Vijay, MD, FAHA Loc Vu, MD, FAHA Quentin R. Youmans, MD, MSc, FAHA CVRI Tadao Aikawa, MD, PhD, FAHA Nicholas Burris, MD, FAHA Patricia Rodriguez-Lozano, MD, MS, FAHA CVSA George Arnaoutakis, MD, FAHA Issac George, MD, FAHA Alina Nicoara, MD, FAHA Daisuke Onohara, MD, PhD, FAHA Ourania Preventza, MD, FAHA Gilbert Tang, MD, FAHA Brittany A. Zwischenberger, MD, MHSc, FAHA CVSN Minjeong An, PhD, RN, FAHA Diana Lyn Baptiste, DNP, MSN, FAHA Eeeseung Byun, PhD, RN, FAHA Jennifer R. Dungan, PhD, MSN, RN, FAHA Kenneth M. Faulkner, PhD, RN, FAHA Michelle Hill, MS, RN, AGCNS-BC, CNRN, SCRN, FAHA Cherlie Magny-Normilus, PhD, FNP-BC, FAHA Helena W. Morrison, PhD, RN, FAHA Kerry Reding, PhD, MPH, RN, FAHA Celeste Surreira, DNP, FNP-BC, FNP-C, CNL, CEN, FAHA EPI Shady Abohashem, MD, MPH, FAHA Emily Ann K. Andaya, MD, MPH, FAHA Leo F. Buckley, PharmD, MPH, FAHA Andreas Kalogeropoulos, MD, PhD, MPH, FAHA Allison L. Kuipers, PhD, FAHA Jing Li, MD, DrPH, MS, FAHA Michelle C. Odden, PhD, FAHA Sanaz Sedaghat, PhD, FAHA Telisa Spikes, PhD, RN, FAHA Jared A. Spitz, MD, FAHA Gabriel Tajeu, DrPH, MPH, FAHA Rebecca C. Thurston, PhD, FAHA Maura Walker, PhD, MS, FAHA Dongshan Zhu, PhD, FAHA GPM Andrew Glazer, PhD, FAHA Yuri Kim, MD, PhD, FAHA HTN Kei Asayama, MD, PhD, FAHA Jill Barnes, PhD, FAHA Lorenzo Carnevale, PhD, FAHA Lama Ghazi, MD, PhD, FAHA Raquibul Hasan, PhD, FAHA Tomoyuki Kabutoya, PhD, FAHA Kenichi Katsurada, MD, PhD, FAHA Juilee Rege, PhD, FAHA Alta Schutte, PhD, FAHA Keisuke Shinohara, MD, PhD, FAHA David Nathaniel Smith, MD, FAHA Srinivas Sriramula, DVM, PhD, FAHA Johannes Stegbauer, MD, FAHA KCVD Uta Erdbruegger, MD, FAHA Lifestyle Liliana Aguayo, PhD, MPH, FAHA Sylvia Badon, PhD, FAHA Neha Khandpur, ScD, FAHA Anurag Mehta, MD, FAHA Rosenda Murillo, PhD, FAHA Satish Patil, PhD, FAHA Shreela Sharma, PhD, FAHA Ariel A. Williamson, PhD, DBSM, FAHA Yaguang Zheng, PhD, RN, FAHA PVD Subhash Banerjee, MD, FAHA Iwan Dakota, MD, PhD, FAHA Hafeez Hassan, MD, FAHA Ki Ho Park, PhD, FAHA David Proctor, PhD, FAHA QCOR Zaid I. Almarzooq, MD, MPH, FAHA Ronen Arbel, PhD, FAHA Doyle M. Cummings, PharmD, FAHA Sanket Dhruva, MD, MHS, FAHA Ismail El Moudden, PhD, FAHA Saket Girotra, MD, SM, FAHA Paul L. Hess, MD, MHS, FAHA Sneha S. Jain, MD, MBA, FAHA Vinay Kini, MD, MSc, FAHA Dhaval Kolte, MD, PhD, MPH, FAHA Amgad N. Makaryus, MD, FAHA Hend Mansoor, PharmD, PhD, FAHA Kalgi Modi, MD, FAHA Chanhyun Park, PhD, FAHA Stroke Alhamza Al-Bayati, MD, FAHA Ammar Alkawi, MD, FAHA Jason Allen, MD, PhD, FAHA Hardik Amin, MD, FAHA Antonio Arauz, PhD, FAHA Sushanth Aroor, MD, FAHA Oluwole Awosika, MD, MSCR, FAHA Muhammad Umer Azeem, MD, FAHA Johannes Boltze, MD, PhD, FAHA Tina Burton, MD, MFA, FAHA Daniel R. Calnan, MD, PhD, FAHA Raphael Arellano Carandang, MD, FAHA Arielle P. Davis, MD, FAHA K. Rose Duncan, MD, MBA, FAHA Sleiman El Jamal, MD, FAHA Heather J. Fullerton, MD, MAS, FAHA Yousef Hannawi, MD, FAHA Mausaminben Hathidara, MD, FAHA Benjamin Kummer, MD, FAHA Susan W. Law, DO, MPH, FAHA Lester Y. Leung, MD, MSc, FAHA Forrest Justin Lowe, MD, FAHA Celia McIntosh, DNP, APRN, FNP-C, PMHNP-BC, SCRN, CNRN, CEN, CCRN, FAANP, FAHA Eliza Miller, MD, MS, FAHA Ivette Motola, MD, MPH, FAHA Fadi Nahab, MD, FAHA Ahmed Nasreldein, MD, PhD, FAHA Sarah E. Nelson, MD, MPH, FAHA Christa O’Hana S. Nobleza, MD, MSCI, FAHA Jorge Ortiz-Garcia, MD, MSCR, FAHA Setareh Salehi Omran, MD, FAHA Edgar Samaniego, MD, FAHA Konrad Schlick, MD, FAHA Laura K. Stein, MD, MPH, FAHA Tushar Trivedi, MD, MPH, PhD, FAHA Rajkumar Verma, MPharm, PhD, FAHA Stephen TC Wong, PhD, FAHA Young Hearts Othman Aljohani, MD, MPH, FAHA Kiona Allen, MD, FAHA Brett Anderson, MD, MBA, MS, FAHA Valeria Duarte, MD, MPH, FAHA Jonathan Edelson, MD, MSCE, FAHA Benjamin S. Frank, MD, FAHA Borah Hong, MD, FAHA Anna Joong, MD, FAHA Nadine Kasparian, PhD, FAHA Ryan Stephens, DNP, MBA, FAHA WELCOME NEW 2026 AMERICAN HEART ASSOCIATION FELLOWS Election as a Fellow of the American Heart Association recognizes the recipient’s scientific accomplishments, leadership and support of the association’s mission. Earning the FAHA credential demonstrates to colleagues and patients that the recipient has been welcomed into one of the world’s most eminent organizations of cardiovascular and stroke professionals. Please join us as we celebrate the new 2026 Fellows of the American Heart Association (FAHA). Scientific Sessions Daily News is produced for the American Heart Association for Scientific Sessions by Ascend Media, LLC (ascendmedia.com). After you have read this issue of Scientific Sessions Daily News, please share with colleagues or deposit it in an approved paper recycling bin. ©2026 by the American Heart Association 7272 Greenville Ave. Dallas, TX 75231 214-570-5935 ScientificSessions.org

RkJQdWJsaXNoZXIy MjI2NjI=